Krystal Biotech reports Q1 2026 progress on KB803, KB801 and VYJUVEK expansion
Krystal Biotech said IOLITE enrollment for KB803 is complete and it remains on track for KB803 and KB801 registrational data readouts in 2026. The company also reported FDA platform technology designations for KB407 and KB111 and continued VYJUVEK expansion.